AI Terminal
Alligator Bioscience
Report Publication Announcement • Dec 4, 2024
3138_rns_2024-12-04_6745c511-9850-435c-8bbe-6f0eec03a226.pdf
Report Publication Announcement
Open in ViewerOpens in native device viewer
ALLIGATOR BIOSCIENCE PUBLISHES FINANCIAL CALENDAR FOR 2025
Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX), hereby publishes its financial calendar for 2025:
| Extraordinary General Meeting | 13 January 2025 |
|---|---|
| Deadline for Alligator Bioscience's shareholders to submit resolutions to be considered by the Annual General Meeting |
31 January 2025 |
| Year-end report 2024 | 22 January 2025 |
| Annual report 2024 | March 2025 |
| Interim report Q1 2025 | 24 April 2025 |
| Annual General Meeting | 7 May 2025 |
| Interim report H1 2025 | 10 July 2025 |
| Interim report Q3 2025 | 23 October 2025 |
| Year-end report 2025 | 12 February 2026 |
For further information, please contact:
Søren Bregenholt, CEO
E-mail: [email protected]
Phone: +46 (0) 46 540 82 00
Johan Giléus, CFO
E-mail: [email protected]
Phone: +46 (0) 46 540 82 00
The information was submitted for publication, through the agency of the contact person set out above, at 08:45 a.m. CET on December 4, 2024.
PRESS RELEASE 04 December 2024 08:45:00 CET
About Alligator Bioscience
Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. Its portfolio includes lead drug candidate mitazalimab, for which the company reported unprecedented survival data at 18-months follow up in first-line metastatic pancreatic cancer patients in Phase 2 testing and is in preparation for Phase 3 development. The follow-on bispecific antibody ATOR-4066 is in preclinical testing. Alligator has a proprietary technology platform, comprised of two antibody libraries, ALLIGATOR-GOLD® and ALLIGATOR-FAB™, the powerful protein optimization strategy FIND® and the bispecific antibody format RUBY™, which drives rapid design and development of innovative drugs.
Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden.
For more information, please visit alligatorbioscience.com.